Executive Summary
Cancer is a leading cause of death worldwide, making early detection and effective treatment is essential. Traditional tissue biopsy has been widely used, but liquid biopsy is emerging as a minimally invasive alternative. It analyzes tumor components in bodily fluids like blood, detecting circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and extracellular vesicles (EVs). Liquid biopsy enables real-time monitoring, early detection, and support adaptive, personalized treatment. Advances in molecular biology and bioinformatics are making it a key tool in precision oncology.
1. Introduction
Cancer is a major public health concern. Early detection and proper treatment improve survival chances. While tissue biopsy is the standard diagnostic method, it cannot fully assess tumor heterogeneity. In recent years, there is a progressive transition from invasive cancer diagnostic technique (i.e., tissue biopsy) to non-invasive techniques, and liquid biopsy is leading as a key alternative. Tumor- associated material can be analyzed through liquid biopsy by sampling biological fluid. Evolving role of liquid biopsies involves selecting adaptive therapies, tracking treatment response, therapy duration and treatment planning. Combined with adaptive therapy, it helps monitor tumor changes, personalize treatment, reduce toxicity, and improve patient survival and quality of life.
2. What is Liquid Biopsy and what is it used for?
3. Adaptive Therapy in Oncology
Adaptive therapy is an innovative and developing approach for cancer treatment. It aims to control, rather than eliminate the tumor by regulating therapy based on how the cancer evolves during the treatment. Unlike traditional treatments, that focuses on destroying as many cancer cells as possible, Adaptive therapy aims to control the tumor growth over time to delay or prevent resistance. Adaptive therapy works with a different approach by:
- Preserving some treatment-sensitive cells to slow down the growth of resistant cells.
- Increase the dose or cease the treatment to maintain the balance for adaptive therapy.
- Adjusts the treatment in real-time basis on how tumor is responding.
3.1 Why it matters?
Bulk sequencing averages signals from many cells, which can hide rare but important populations like cancer stem cells or drug-resistant cells. It also struggles to detect low frequency mutations and cannot distinguish whether gene expression comes from cancer, immune, or normal cells. As a result, it provides limited insight into tumor evolution, clonal relationships, and how cancers adapt to treatment.
4. Key Liquid Biopsy Techniques
Liquid biopsy approaches, including the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), circulating miRNAs, and tumor-derived extracellular vesicles (EVs) are most common tumor-related biomarkers assessed on liquid biopsy so far. They offer an effective way to diagnose and track the progress over the time.
Three major Liquid biopsy techniques:
5. Benefits of Liquid Biopsy in Cancer management
- Non-invasive and safe: Liquid biopsy uses body fluids instead of surgery, making it safer, less painful, and repeatable
- Real-time monitoring: Helps track tumor changes and treatment response through biomarkers like ctDNA and CTCs.
- Early detection and recurrence monitoring: Detects cancer early and identifies minimal residual disease (MRD) to prevent relapse.
- Guided personalized therapy: Supports precision treatment by identifying the most effective therapies and monitoring outcomes.
- Identifying resistance mutations: Detects tumor mutations and treatment resistance using ctDNA, CTCs, and extra cellular vesicle analysis.
6. Liquid Biopsy vs. Traditional Biopsy
7. Applications of liquid biopsy according to the type of cancer
8. IP Activity in Liquid Biopsy
As part of our analysis of patent activity in Liquid Biopsy technique, an IP landscape study was conducted to identify patents related to the Liquid biopsy as a non-invasive diagnostic technique to detect and analyze tumor cells. A total of 694 patents application were analyzed.
8.1 Relevant keywords and synonyms used for search
- Liquid biopsy, fluid biopsy, fluid phase biopsy, Blood Biopsy, Urine Biopsy, Saliva Biopsy
- Non-invasive, Non-Surgical, Non-intrusive, Needle-free
- Technique, Method, Approach, Strategy, System, Procedure
- detect, Identifying, Analyze, Diagnosis, Recognize, Monitoring
- Tumor cells, Cancer cells, Malignant cells, Neoplastic cells, Oncogenic cells
8.2 Graphical Analysis from the identified patents (649 patent applications):
Figure 7 shows a pie chart illustrates the distribution of patents by status, with 478 classified as Active and 216 as Inactive.
Figure 8 shows the distribution of patents across priority countries, highlighting major R&D hubs. China leads with 185 patents, followed by WO with 148 patents, and Genopsy Co Ltd holds the largest share of patents in the Chinese jurisdiction.
Figure 9 Shows top patent assignees include Genopsy Co Ltd, leading with 28 patents focused on advancing liquid biopsy as a non-invasive diagnostic method for detecting and analyzing tumor cells. This is followed by Natera Inc with 23 patents and Guardant Health with 22 patents.
9. Market and Commercial Outlook
The global liquid biopsy market size was estimated at USD 13.60 billion in 2025 and is projected to reach USD 32.57 billion by 2033, growing at a CAGR of 11.52% from 2026 to 2033. The industry is witnessing growth due to factors such as the growing prevalence of cancer, technological advancements in cancer diagnostics, and rising preference for minimally invasive cancer diagnostics.
Source: https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
Ongoing advancements in liquid biopsy assays and the growing adoption of multi-cancer early detection tests are creating significant growth opportunities in the market. Liquid biopsy enables non-invasive detection of tumor-related genetic alterations and supports personalized cancer treatment. Recent developments, such as early detection tests are creating significant growth opportunities in the market. Liquid biopsy enables non-invasive detection of tumor-related genetic alterations and supports personalized cancer treatment. Guardant Health receiving FDA approval for Guardant360 CDx in 2023 for ESR1 mutant breast cancer diagnosis, are further accelerating market growth.
Source: https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
9.1 Product Insights
The instruments segment led the liquid biopsy market in 2025, accounting for 47.10% of revenue, driven by new product launches and technological advancements. For example, Guardant Health enhanced its Guardant360 platform in May 2025 with advanced cancer subtyping and biomarker identification features powered by AI.
source: https://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
10. Future Directions
Liquid biopsy is rapidly advancing as a transformative tool in precision oncology due to its minimally invasive, repeatable, and real-time approach to cancer detection and monitoring. Ongoing innovations in molecular biology, bioinformatics, and clinical oncology are driving the development of advanced liquid biopsy platforms that improve tumor analysis and support personalized treatment strategies. These advancements are enhancing early cancer detection, guiding therapy selection, monitoring drug resistance, and enabling long-term disease tracking, positioning liquid biopsy as a key component of future patient-centered cancer care. The future of cancer care will completely rely on the dynamic, data-rich and patient- centered approach that liquid biopsy enables- offering a more personalized, adaptive and predictive pattern in oncology.
11. Conclusion
Liquid biopsy is revolutionizing cancer diagnosis and management by offering a minimally invasive, safe, and repeatable alternative to traditional tissue biopsies. By analyzing tumor-derived biomarkers such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles in body fluids, it enables real-time monitoring of tumor behavior, early cancer detection, and personalized treatment strategies. Its ability to capture tumor heterogeneity, identify mutations, and monitor treatment response improves patient outcomes and quality of life. With ongoing advancements in research and technology, liquid biopsy is becoming an essential tool in precision oncology, supporting more adaptive and effective cancer care.
